Donate to Science & Enterprise

S&E on Mastodon

S&E on LinkedIn

S&E on Flipboard

Please share Science & Enterprise

Merger to Form Programmable Nano-Medicines Company

Molecule model in an open hand

A life science venture investor is merging two of its biotechnology portfolio companies to form a single developer of nanoscale medications with programmable properties. . . . → Read More: Merger to Form Programmable Nano-Medicines Company

Organ Chip Devices to Model for Radiation Sickness

Organ on a chip

The U.S. government’s health preparedness agency awarded a contract with a university lab to explore organ models on chips to document effects of radiation sickness. . . . → Read More: Organ Chip Devices to Model for Radiation Sickness

Start-Up Adapts Crispr for Molecular Detection, Raises $40M

Crispr graphic

A new company is underway that says it adapts the gene editing technique Crispr to make detecting nucleic acid targets like DNA or RNA faster and simpler. . . . → Read More: Start-Up Adapts Crispr for Molecular Detection, Raises $40M

High-Speed Biologic Injection Device Shown Feasible

Racing motorcycle

A developer of an auto-injection technology says its device can deliver a biologic drug under the skin in a fraction of the time of conventional syringes. . . . → Read More: High-Speed Biologic Injection Device Shown Feasible

Genetic Tests of Breast Cancer Patients Shown Useful

Breast cancer cell

Experiences from a rural hospital in North Carolina show hereditary genetic testing of all breast cancer patients is feasible and can result in changes in care for many patients. . . . → Read More: Genetic Tests of Breast Cancer Patients Shown Useful

Longevity Science Group Spins-Off Biotech Start-Up

Naked mole rat on black background

An organization funding research on extending the human life span by preventing age-related diseases is founding its first biotechnology company. . . . → Read More: Longevity Science Group Spins-Off Biotech Start-Up

Collapsed Microbiome Biotech Sells Off Assets

Microbiome illustration

A developer of therapies addressing the body’s microbe communities is selling off key assets to another biotechnology company, after problems developed with its lead program. . . . → Read More: Collapsed Microbiome Biotech Sells Off Assets

Neuro Disease Biotech Gains $61M in Early Funds

Brain cell networks

A developer of treatments for Alzheimer’s disease that seeks to improve the condition of the brain’s support cells is raising £48 million ($US 61 million) in its first venture round. . . . → Read More: Neuro Disease Biotech Gains $61M in Early Funds

NIH Funds Antibody Discovery for Difficult Protein Targets

Chicken on a wooden floor

A biotechnology company is receiving NIH support for discovering antibodies that address the vast majority of proteins coded by the human genome, passed-up so far by drug makers. . . . → Read More: NIH Funds Antibody Discovery for Difficult Protein Targets

Vaccine Shown to Protect Against Multiple Hospital Pathogens

MRSA bacteria

Research with lab mice shows an experimental vaccine stimulates the body’s basic immune system to protect against a range of pathogens associated with hospital infections. . . . → Read More: Vaccine Shown to Protect Against Multiple Hospital Pathogens